Precision Medicine for the Wellbeing of the Patient?
April 11, 2019
09:30 - 11:00
_Stage C, Hall 4.2
Genomic high throughput procedures enable the molecular components of diseases to be examined in detail. Increasingly the molecular profiling of patients is taking place not only in the course of clinic investigations but also in routine clinical care. On the one hand this has led to expectations of highly adapted therapies for individual patients, but on the other it has revealed other new challenges. For example, it will not be possible to manufacture a precisely targeted medication for each individual patient, and in fact the patient categories that have until now been registered in larger groups are being broken down into a great number of sub-groups with uncertain consequences for their targeted treatment. This leaves many clinicians in a state of uncertainty and consequently cases in which the primary treatment in accordance with specified guidelines is not effective are often presented in highly specialized, interdisciplinary therapy boards. However, the question also arises as to whether patients are willing to accept a few days’ or weeks’ uncertainty about the success of a therapy while at the same time experiencing serious side effects. In the final analysis there is some doubt about who should meet the costs of what are in some cases very extensive therapies.
In this track we adopt the perspective of the patients, clinician and cost providers, and look forward to a lively discussion with the panel that follows.
Dr. Martin Lablans, Head of Department, German Cancer-research Center
Prof. Ulrich Sax, Commissioner of the Institute of Medical Informatics, University Medical Center Göttingen
Prof. Tibor I. Kesztyüs, Professor, Ulm University
Anna Kron, Management of the nNGM office, University Hospital Cologne
Dr. Thomas Helms, Board Member, Deutsche Stiftung für chronisch Kranke